市場調査レポート

商品コード

1447728

慢性蕁麻疹市場の評価：治療法・診断・投与経路・エンドユーザー・地域別の機会および予測 (2017～2031年)

Chronic Spontaneous Urticaria Market Assessment, By Treatment, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月11日
発行: Market Xcel - Markets and Data
ページ情報: 英文 225 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,500 648,270円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 821,142円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,181,292円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.06円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の慢性蕁麻疹の市場規模は、2023年の20億1,000万米ドルから、2024年から2031年の予測期間中は11.93%のCAGRで推移し、2031年には49億5,000万米ドルの規模に成長すると予測されています。

慢性蕁麻疹の有病率の増加、R&Dへの多額の投資、治療に適した薬剤の入手可能性、皮下注射薬の臨床的優位性、臨床試験の増加など、さまざまな要因が世界の慢性蕁麻疹市場を形成しています。慢性蕁麻疹の世界市場は、画期的な発見や病気に対する理解の深まりにより大きく拡大しています。

蕁麻疹の基本的なメカニズムの徹底的な解明により、より強力な治療薬が生み出されつつあります。製薬会社や医療提供者からのR&D資金の増加により、新たな治療法が発見され、市場に導入されています。慢性蕁麻疹の病態生理に関する知識の向上は、従来のアプローチよりも優れた症状緩和をもたらす、より効果的なテーラーメード医薬品の開発につながっています。世界の慢性蕁麻疹市場は、薬剤の皮下投与が可能になったことも影響しています。この方法は、患者の末梢系に影響を与えることなく薬剤を完全に吸収でき、血管や神経を傷つける可能性もないため、非常に効果的です。

Novartisは2023年8月、慢性蕁麻疹患者を対象としたBTK阻害剤レミブルチニブ25mg b.i.d.を評価する第III相REMIX-1およびREMIX-2試験の良好なトップラインデータを報告しました。レミブルチニブが承認されれば、慢性蕁麻疹を治療する10年ぶりの薬剤となる可能性があり、H1-抗ヒスタミン薬が無効な患者の60％に、簡便で効率的な代替薬を提供することになります。

R&D促進のための多額の投資

世界の慢性蕁麻疹市場の成長は、製薬企業によるR&D活動への絶え間ない注力によっても牽引されています。市場の主要企業は、慢性蕁麻疹の患者を治療するための革新的な解決策を見出すための研究活動に巨額を投じています。研究を通じて、企業は本疾患の治療を取り巻く要因についてさまざまな洞察を得ることができます。

医療インフラ改善のための多額の投資

効率的な慢性蕁麻疹治療に対するニーズが高まっていることを受け、世界の慢性蕁麻疹市場の主要企業は、投資を通じて医療インフラの改善に向けた取り組みを強化しています。このような計算された行動は、慢性蕁麻疹の発症率の上昇を動機としています。慢性蕁麻疹は、突然発症し、明確な理由がない腫れや蕁麻疹を特徴とする疾患です。これらの企業は、医療インフラにより多くの資金を投入することで、より強力で新しい治療法を生み出し、提供することを望んでいます。慢性蕁麻疹患者のアンメットニーズを満たすための献身を示すだけでなく、この投資は、より良い治療が患者の良好な転帰をもたらし、最先端の治療に対する需要が高まることにより、市場が大きく発展する可能性があることを示しています。

当レポートでは、世界の慢性蕁麻疹の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
治療別
- 薬剤
- 血漿交換
- 光線療法
- その他
診断別
- 血液検査
- アレルギー検査
- 身体検査
- その他
投与経路別
- 経口
- 局所
- 非経口
- その他
エンドユーザー別
- 病院
- 専門クリニック
- ホームケア
- その他
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
企業別の市場シェア

第5章世界の慢性蕁麻疹市場の展望：地域別

北米
欧州
南米
アジア太平洋
中東・アフリカ

第6章市場マッピング

治療別
診断別
投与経路別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長阻害要因 (課題・抑制要因)

第9章規制の枠組みとイノベーション

臨床試験
特許の情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (主要企業)
特許分析 (該当する場合)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
Sanofi S.A.
Pfizer Inc.
GlaxoSmithKline plc
Novartis AG
Bayer AG
Eli Lilly and Company
Merck & Co., Inc.
AstraZeneca plc

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 2.Global Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 3.Global Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 4.Global Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 5.Global Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 6.Global Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 7.Global Chronic Spontaneous Urticaria Market Share (%), By Region, 2017-2031F
Figure 8.North America Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 9.North America Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 10.North America Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 11.North America Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 12.North America Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 13.North America Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 14.North America Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
Figure 15.United States Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 16.United States Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 17.United States Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 18.United States Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 19.United States Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 20.United States Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 21.Canada Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 22.Canada Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 23.Canada Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 24.Canada Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 25.Canada Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 26.Canada Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 27.Mexico Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 28.Mexico Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 29.Mexico Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 30.Mexico Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 31.Mexico Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 32.Mexico Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 33.Europe Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 34.Europe Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 35.Europe Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 36.Europe Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 37.Europe Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 38.Europe Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 39.Europe Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
Figure 40.Germany Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 41.Germany Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 42.Germany Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 43.Germany Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 44.Germany Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 45.Germany Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 46.France Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 47.France Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 48.France Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 49.France Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 50.France Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 51.France Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 52.Italy Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 53.Italy Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 54.Italy Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 55.Italy Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 56.Italy Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 57.Italy Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 58.United Kingdom Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 59.United Kingdom Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 60.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 61.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 62.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 63.United Kingdom Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 64.Russia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 65.Russia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 66.Russia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 67.Russia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 68.Russia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 69.Russia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 70.Netherlands Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 71.Netherlands Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 72.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 73.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 74.Netherlands Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 75.Netherlands Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 76.Spain Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 77.Spain Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 78.Spain Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 79.Spain Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 80.Spain Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 81.Spain Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 82.Turkey Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 83.Turkey Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 84.Turkey Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 85.Turkey Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 86.Turkey Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 87.Turkey Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 88.Poland Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 89.Poland Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 90.Poland Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 91.Poland Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 92.Poland Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 93.Poland Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 94.South America Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 95.South America Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 96.South America Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 97.South America Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 98.South America Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 99.South America Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 100.South America Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
Figure 101.Brazil Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 102.Brazil Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 103.Brazil Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 104.Brazil Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 105.Brazil Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 106.Brazil Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 107.Argentina Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 108.Argentina Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 109.Argentina Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 110.Argentina Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 111.Argentina Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 112.Argentina Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 113.Asia-Pacific Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 114.Asia-Pacific Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 115.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 116.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 117.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 118.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 119.Asia-Pacific Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
Figure 120.India Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 121.India Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 122.India Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 123.India Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 124.India Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 125.India Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 126.China Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 127.China Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 128.China Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 129.China Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 130.China Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 131.China Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 132.Japan Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 133.Japan Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 134.Japan Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 135.Japan Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 136.Japan Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 137.Japan Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 138.Australia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 139.Australia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 140.Australia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 141.Australia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 142.Australia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 143.Australia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 144.Vietnam Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 145.Vietnam Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 146.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 147.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 148.Vietnam Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 149.Vietnam Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 150.South Korea Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 151.South Korea Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 152.South Korea Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 153.South Korea Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 154.South Korea Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 155.South Korea Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 156.Indonesia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 157.Indonesia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 158.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 159.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 160.Indonesia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 161.Indonesia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 162.Philippines Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 163.Philippines Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 164.Philippines Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 165.Philippines Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 166.Philippines Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 167.Philippines Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 168.Middle East & Africa Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 169.Middle East & Africa Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 170.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 171.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 172.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 173.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 174.Middle East & Africa Chronic Spontaneous Urticaria Market Share (%), By Country, 2017-2031F
Figure 175.Saudi Arabia Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 176.Saudi Arabia Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 177.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 178.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 179.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 180.Saudi Arabia Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 181.UAE Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 182.UAE Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 183.UAE Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 184.UAE Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 185.UAE Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 186.UAE Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 187.South Africa Chronic Spontaneous Urticaria Market, By Value, In USD Billion, 2017-2031F
Figure 188.South Africa Chronic Spontaneous Urticaria Market, By Volume, In Thousand Units, 2017-2031F
Figure 189.South Africa Chronic Spontaneous Urticaria Market Share (%), By Treatment, 2017-2031F
Figure 190.South Africa Chronic Spontaneous Urticaria Market Share (%), By Diagnosis, 2017-2031F
Figure 191.South Africa Chronic Spontaneous Urticaria Market Share (%), By Route of Administration, 2017-2031F
Figure 192.South Africa Chronic Spontaneous Urticaria Market Share (%), By End-user, 2017-2031F
Figure 193.By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194.By Diagnosis Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11135

The chronic spontaneous urticaria market is projected to witness a CAGR of 11.93% during the forecast period 2024-2031, growing from USD 2.01 billion in 2023 to USD 4.95 billion in 2031. Various factors are shaping the global chronic spontaneous urticaria market such as the increasing prevalence of chronic spontaneous urticaria, significant investments in research and development, availability of suitable medications for treatment, clinical advantages of subcutaneous drugs, and increasing number of clinical trials. The global chronic spontaneous urticaria market, which is defined by recurring hives and angioedema without known triggers, is expanding significantly due to breakthrough discoveries and a better comprehension of the illness.

The creation of more potent treatments is being fueled by a more thorough investigation of the fundamental mechanisms of CSU. New therapeutic options are being discovered and introduced in the market through increased research and development funding from pharmaceutical companies and healthcare providers. Improved knowledge of the pathophysiology of CSU is leading to more effective tailored medicines that provide better symptom alleviation than conventional approaches. The global chronic spontaneous urticaria market is affected by the ability to administer medications subcutaneously. The method is highly effective as it allows complete absorption of the drug without affecting patient's peripheral system and no chances of injury to the vessels and nerves.

Novartis reported positive top-line data in August 2023 from the Phase III REMIX-1 and REMIX-2 studies assessing the BTK inhibitor remibrutinib 25 mg b.i.d. in patients with chronic spontaneous urticaria (CSU). Remibrutinib, if authorized, could be the first medication in a decade to treat chronic spontaneous urticaria (CSU), providing a straightforward and efficient alternative for 60% of patients for whom H1-antihistamines are ineffective.

Significant Investments for Expediting Research and Development

The growth of global chronic spontaneous urticaria market is being driven by a constant focus on research and development activities by pharmaceutical companies. Major companies in the market are spending huge amounts in conducting research activities to find innovative solutions for treating patients with CSU. Through research, companies can discover various insights into the factors revolving around the treatment of the disease. All these factors indicate that there is a strong association between the research efforts and the increasing growth trajectory of the global chronic spontaneous urticaria market. In January 2024, Enanta Pharmaceuticals, a clinical-stage biotechnology company, provided updates on its research and development programs and the outlook for the year 2024, at the 42nd Annual J.P. Morgan healthcare conference. The company announced its expansion into immunology and discovery programs to treat CSU.

Significant Investments for Improving Healthcare Infrastructure

Noticing the increasing need for efficient CSU therapies, major players in the global chronic spontaneous urticaria market are stepping up their efforts to improve healthcare infrastructure through investments. The calculated action is motivated by the rising incidence of CSU, a disorder marked by swelling and hives that develop suddenly and have no apparent reason. These businesses hope to create and offer novel, more potent treatment alternatives by investing more money in the healthcare infrastructure. In addition to demonstrating their dedication to meet the unmet needs of CSU patients, the investment shows the market has the potential to develop significantly due to better treatments resulting in favorable patient outcomes and a rise in demand for cutting-edge therapies.

Many companies in the global chronic spontaneous urticaria market are increasing their investments in the market. For instance, in April 2023, Evommune, Inc. announced the completion of USD 50 million Series B financing to develop new innovative technologies to treat inflammatory diseases such as CSU. Along with current investors EQT Life Sciences and SymBiosis, new investor Arix Bioscience led the funding.

Availability of Novel Medications for Treatment

The development and accessibility of therapeutic alternatives, such as immunosuppressants, biologic therapies, and antihistamines, are the main factors driving the global chronic spontaneous urticaria market. These medications are highly effective due to which their demand in the market is increasing drastically. Medical research advancements have led to the development of many such medications, with more under clinical trials. Second-line drugs like leukotriene receptor antagonists (like montelukast), oral corticosteroids (like prednisone), H2 blockers (like cimetidine), and biologics (like omalizumab; Xolair) may be prescribed to treat patients with refractory symptoms. In January 2024, Evommune, Inc., a clinical-stage biotechnology company, announced the beginning of its human study for Phase 1, to find out EVO756 in adults with CSU. If the trial turns out to be successful, then EVO756 can be the first oral treatment for several diseases such as CSU and inflammatory itch.

Clinical Advantages of Subcutaneous Drugs

Subcutaneous drugs absorb easily without any side effects. Subcutaneous drugs offer numerous clinical benefits such as patient convenience, reduced cost, fewer side effects, enhanced patient satisfaction, and improved drug absorption. With less frequent doses and consistent medication absorption, it can potentially minimize the need for hospital visits and increase patient compliance by enabling self-administration at home. Subcutaneous drugs are highly effective offering a reliable treatment for CSU. Home administration eliminates the need for expensive hospital visits and decreases the demand for medical personnel, resulting in lower healthcare expenses. Compared to intravenous administration, subcutaneous administration often leads to fewer adverse events, particularly those related to infusions, such as infections and hypersensitivity reactions.

On February 16, 2024, Genentech, a member of Roche Group, announced Xolair for the treatment of anaphylaxis and allergic reactions caused due to food allergies in children and adults. It received approval from the U.S. Food and Drug Administration (FDA) and has been cleared for use of treating CSU.

Asia-Pacific to Grow at the Fastest Rate During the Forecast Period

Several countries in Asia-Pacific are going to observe rapid growth in the global chronic spontaneous urticaria market. Economic growth in countries like China and India is going to play a major role in market expansion along with the countries such as China, Japan, India, Australia, and South Korea. The trend can be attributed to the region's increasing population growth, government initiatives, and improving healthcare infrastructure. People are becoming more aware of the illness and its implications, which increases the demand for effective therapies. Additionally, by giving patients more treatment options, the emergence of new pharmaceutical businesses in the market with a focus on cutting-edge CSU therapy promotes market expansion.

On 16 February 2024, Dupixent, a drug used for the treatment of CSU, jointly developed by Sanofi and Regeneron, was granted permission for manufacturing and marketing by the Ministry of Health, Labour and Welfare (MHLW) in Japan.

Future Market Scenario (2024 - 2031F)

To handle the complexity of CSU, businesses are actively seeking novel solutions. For example, Amalizumab, a monoclonal antibody that targets immunoglobulin E (IgE), was developed and is now authorized for use in CSU.

It is anticipated that the creation of novel diagnostic instruments and methodologies will enhance the precision and promptness of CSU diagnosis, resulting in improved patient outcomes. For instance, blood and skin prick tests can be used to determine the underlying cause of CSU, which enables doctors to adjust treatment regimens accordingly.

Advancement in treatment options like targeted therapies and biologics will lead to the expansion of the global spontaneous urticaria market.

Patients are more likely to receive access to cutting-edge CSU medicines and treatments as global healthcare spending rises.

Key Players Landscape and Outlook

The chronic spontaneous urticaria market is expected to experience significant growth in the coming years, driven by factors such as increasing prevalence of urticaria, rising healthcare spending, and technological advancements in medicine and digital health. The market is highly competitive, with key players including Roche, Novartis, Sanofi, AstraZeneca, and GlaxoSmithKline, and others. The global chronic spontaneous urticaria market is witnessing a significant shift towards strategic partnerships among leading companies in the industry. By working together, these organizations can overcome technical and clinical barriers that would otherwise prevent them from moving forward independently.

A Complete Response Letter (CRL) for the supplementary Biologics Licence Application for Dupixent was made available by the U.S. FDA in October 2023. A medication called Dupixent used to treat CSU, is being developed in collaboration with the American biotechnology company Regeneron and Sanofi.

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Chronic Spontaneous Urticaria Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1.By Value
- 4.1.2.By Volume
4.2.By Treatment
- 4.2.1.Medication
- 4.2.2.Plasmapheresis
- 4.2.3.Phototherapy
- 4.2.4.Others
4.3.By Diagnosis
- 4.3.1.Blood Test
- 4.3.2.Allergy Test
- 4.3.3.Physical Examination
- 4.3.4.Others
4.4.By Route of Administration
- 4.4.1.Oral
- 4.4.2.Topical
- 4.4.3.Parenteral
- 4.4.4.Others
4.5.By End-user
- 4.5.1.Hospitals
- 4.5.2.Specialty Clinics
- 4.5.3.Homecare
- 4.5.4.Others
4.6.By Region
- 4.6.1.North America
- 4.6.2.Europe
- 4.6.3.Asia-Pacific
- 4.6.4.South America
- 4.6.5.Middle East and Africa
4.7.By Company Market Share (%), 2023

5.Global Chronic Spontaneous Urticaria Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Treatment
  - 5.1.2.1.Medication
  - 5.1.2.2.Plasmapheresis
  - 5.1.2.3.Phototherapy
  - 5.1.2.4.Others
- 5.1.3.By Diagnosis
  - 5.1.3.1.Blood Test
  - 5.1.3.2.Allergy Test
  - 5.1.3.3.Physical Examination
  - 5.1.3.4.Others
- 5.1.4.By Route of Administration
  - 5.1.4.1.Oral
  - 5.1.4.2.Topical
  - 5.1.4.3.Parenteral
  - 5.1.4.4.Others
- 5.1.5.By End-user
  - 5.1.5.1.Hospitals
  - 5.1.5.2.Specialty Clinics
  - 5.1.5.3.Homecare
  - 5.1.5.4.Others
- 5.1.6.United States*
  - 5.1.6.1.Market Size & Forecast
  - 5.1.6.1.1.By Value
  - 5.1.6.1.2.By Volume
  - 5.1.6.2.By Treatment
  - 5.1.6.2.1.Medication
  - 5.1.6.2.2.Plasmapheresis
  - 5.1.6.2.3.Phototherapy
  - 5.1.6.2.4.Others
  - 5.1.6.3.By Diagnosis
  - 5.1.6.3.1.Blood Test
  - 5.1.6.3.2.Allergy Test
  - 5.1.6.3.3.Physical Examination
  - 5.1.6.3.4.Others
  - 5.1.6.4.By Route of Administration
  - 5.1.6.4.1.Oral
  - 5.1.6.4.2.Topical
  - 5.1.6.4.3.Parenteral
  - 5.1.6.4.4.Others
  - 5.1.6.5.By End-user
  - 5.1.6.5.1.Hospitals
  - 5.1.6.5.2.Specialty Clinics
  - 5.1.6.5.3.Homecare
  - 5.1.6.5.4.Others
- 5.1.7.Canada
- 5.1.8.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1.Germany
- 5.2.2.France
- 5.2.3.Italy
- 5.2.4.United Kingdom
- 5.2.5.Russia
- 5.2.6.Netherlands
- 5.2.7.Spain
- 5.2.8.Turkey
- 5.2.9.Poland
5.3.Asia-Pacific
- 5.3.1.India
- 5.3.2.China
- 5.3.3.Japan
- 5.3.4.Australia
- 5.3.5.Vietnam
- 5.3.6.South Korea
- 5.3.7.Indonesia
- 5.3.8.Philippines
5.4.South America
- 5.4.1.Brazil
- 5.4.2.Argentina
5.5.Middle East & Africa
- 5.5.1.Saudi Arabia
- 5.5.2.UAE
- 5.5.3.South Africa

6.Market Mapping, 2023

6.1.By Treatment
6.2.By Diagnosis
6.3.By Route of Administration
6.4.By End-user
6.5.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.5.1.Supplier Power
- 7.5.2.Buyer Power
- 7.5.3.Substitution Threat
- 7.5.4.Threat from New Entrant
- 7.5.5.Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Clinical Trials
9.2.Patent Landscape
9.3.Regulatory Approvals
9.4.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)
10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.F. Hoffmann-La Roche Ltd.
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.Teva Pharmaceutical Industries Ltd.
13.3.Sanofi S.A.
13.4.Pfizer Inc.
13.5.GlaxoSmithKline plc
13.6.Novartis AG
13.7.Bayer AG
13.8.Eli Lilly and Company
13.9.Merck & Co., Inc.
13.10.AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

慢性蕁麻疹市場の評価：治療法・診断・投与経路・エンドユーザー・地域別の機会および予測 (2017～2031年)

Chronic Spontaneous Urticaria Market Assessment, By Treatment, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の慢性蕁麻疹市場の展望

第5章世界の慢性蕁麻疹市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Chronic Spontaneous Urticaria Market Outlook, 2017-2031F

5.Global Chronic Spontaneous Urticaria Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

慢性蕁麻疹市場の評価：治療法・診断・投与経路・エンドユーザー・地域別の機会および予測 (2017～2031年)

Chronic Spontaneous Urticaria Market Assessment, By Treatment, By Diagnosis, By Route of Administration, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の慢性蕁麻疹市場の展望

第5章 世界の慢性蕁麻疹市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Chronic Spontaneous Urticaria Market Outlook, 2017-2031F

5.Global Chronic Spontaneous Urticaria Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界の慢性蕁麻疹市場の展望

第5章世界の慢性蕁麻疹市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項